Nanjing Vcare Successfully Passed the Recognition of "High-tech Enterprise"

2023-12-27

In late December 2023, the Office of the National High-tech Enterprise Recognition and Management Leading Group released the "List of the Second Batch of High-tech Enterprises Filed for Recognition and Reporting by the Recognition Institutions in Jiangsu Province in 2023". Nanjing Vcare was on the list and officially became a national high-tech enterprise.

The high-tech enterprise is a special qualification recognition established by the state to support and encourage the development of enterprises in the high-tech field, adjust the industrial structure and enhance the national economic competitiveness. The National High-tech Enterprise Recognition and Management Leading Group jointly established by the Ministry of Science and Technology, the Ministry of Finance and the State Taxation Administration comprehensively evaluates multiple indicators of enterprises, such as core technologies, independent intellectual property rights, the proportion of scientific talents, and R&D investment. The recognition standards are strict and the recognition procedures are rigorous.

Since independently operating the whole-industry-chain CRO/CDMO business of drugs in 2021, Nanjing Vcare has always adhered to innovation-driven development, continuously increased R&D investment, and strengthened the introduction and cultivation of highly skilled talents to strengthen the foundation and empower the high-quality development of the enterprise. The successful passing of the recognition of "high-tech enterprise" this time is not only a high recognition of the achievements made by Nanjing Vcare in the technical field, patent achievements, R&D investment, growth indicators, talent structure and other aspects, but also has a positive promoting effect on Nanjing Vcare's further improvement of its independent innovation ability and acceleration of building a domestic first-class and internationally renowned R&D and production service platform covering the whole industrial chain and the whole life cycle of chemical drugs. Nanjing Vcare will further increase investment in R&D and innovation, deepen the construction of the talent team, enhance technical capabilities and service levels, and continuously improve the core competitiveness of the enterprise to promote its high-quality development.

Prev

Tianshu Pharmaceutical, the Production Base of Nanjing Vcare, Was Approved for the "Drug Production License", Adding a New Engine to the Whole-Industrial-Chain Layout

Next

PhaseⅠ Project of Tianshu Pharmaceutical, the Production Base of Nanjing Vcare, Entered the Trial Production Stage